1. On election of the Supervisory Board of joint-stock company „Reverta” To elect for the office of the member of joint-stock company „Reverta” Supervisory Board for the term of 3 (three) years, starting on 1 August 2013: 1. Michael Joseph Bourke, 2. Mary Ellen Collins, 3. Kaspars ?boli?š, 4. Andris Ozoli?š. Voting results: decision is taken by dividing the votes. To determine monthly remuneration (gross) for the members of joint-stock company „Reverta” Supervisory Board as follows: 1) Chairman of Supervisory Board LVL 3000; 2) Deputy Chairman of Supervisory Board LVL 2500; 3) Member of Supervisory Board LVL 2000. Voting results: decision is taken with the required majority of the votes. 2. On approval of the new edition of rules of procedure of Audit Committee of joint-stock company “Reverta” To approve the new edition of rules of procedure of Audit Committee of joint-stock company “Reverta” (enclosed). Voting results: decision is taken with the required majority of the votes. The experience of newly elected council members of AS Reverta over the past years: Kaspars ?boli?š has significant experience in the financial sector. He has worked for institutions such as the Latvian Ministry of Finance and the State Real Estate Agency. In 2006 he became governor of the National Treasury, and since 2011 he has been board director of the Nordic Investment Bank. Andris Ozoli?š has extensive experience in bank management. He was board chairman and president of the DNB Bank from 2004 until 2012 and a board member at the bank from 1999 until 2004. From 2008 until 2011 he was council chairman of the Latvian Association of Commercial Banks. The members of the Supervisory Board have no shares of the JSC “Reverta” . Riga, July 26, 2013 JSC „Reverta” Management Board For additional infomation contact: Marita Ozolina Head of Communications and Marketing Department Phone: 67779142 or 29287169, E-mail: marita.ozolina@reverta.lv
AS "Reverta" DECISIONS of extraordinary shareholders
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Ovation's Roadmap for Revitalizing Rural Healthcare
Steering Rural Healthcare Towards a Brighter Future Alright, here we are with Ovation Healthcare trying to inject some much-needed life into the sometimes forgotten corners of the healthcare world—those rural hospitals. They’ve cooked up a fresh white paper, and it’s got the makings of a lifeline for these institutions swirling in red ink. The financial landscape...
Continue Reading
ProperHeir Expands with New Innovative Office Space
ProperHeir Expands with New Innovative Office Space ProperHeir has recently announced an exciting development with the opening of its new office at the Miramar Tech Center. This expansion marks a significant milestone as the company has tripled its available space. The chief purpose of this new office is to effectively host its growing in-house sales team and provide a...
Continue Reading
Discover How Octa Transforms Forex Trading for Singaporeans
Understanding the Forex Market The foreign exchange market, commonly known as forex, stands as the largest and most dynamic financial market in the world. It allows traders to buy and sell currencies, leveraging the fluctuations in exchange rates to boost their earnings. Operating continuously from Monday to Friday, this market presents individual traders with the chance...
Continue Reading
Seoul Business Agency Powers Startups at the CES 2026 Pavilion
Seoul Business Agency Showcases Startups at CES 2026 Pavilion The Seoul Business Agency (SBA) has taken ambitious strides to support the innovative spirit of Seoul's startups at CES 2026. Engaging with 19 prestigious institutions within Seoul’s ecosystem, the SBA is dedicated to empowering 70 startups as they venture onto the global stage. The 'Seoul POP' themed...
Continue Reading
VYJUVEK® Receives Groundbreaking Approval for DEB Treatment
VYJUVEK® Approved for Dystrophic Epidermolysis Bullosa Treatment VYJUVEK approved for DEB treatment from birth, offering flexible home administration options for patients and their families. This breakthrough marks VYJUVEK as the first genetic medicine approved in Japan for DEB. Recently, Krystal Biotech, Inc. (NASDAQ: KRYS) announced that its innovative treatment,...
Continue Reading